Response to the comment of Mr. J. Henderson on paper “Anaesthesia in the colagenase clostridium histolyticum injection for Dupuytren's disease: A cohort analysis”✰

2019 ◽  
Vol 72 (3) ◽  
pp. 513-527
Author(s):  
Rafael Sanjuan-Cervero
Keyword(s):  
Cohort Analysis ◽  
Dupuytren’S Disease ◽  
Dupuytren's Disease ◽  
Clostridium Histolyticum

Recurrent Dupuytren’s disease after fasciectomy and collagenase injection are histologically indistinguishable

2020 ◽  
Vol 45 (5) ◽  
pp. 508-512
Author(s):  
Rafael Sanjuan-Cervero ◽  
Francisco J. Carrera-Hueso ◽  
Manuel Vaquero-Perez ◽  
Daniel Montaner-Alonso
Keyword(s):  
Cohort Study ◽  
Prospective Cohort ◽  
Previous Treatment ◽  
Disease Recurrence ◽  
Dupuytren’S Disease ◽  
Collagenase Clostridium Histolyticum ◽  
Dupuytren's Disease ◽  
Clostridium Histolyticum ◽  
Collagenase Injection ◽  
Previously Treated

The aim of this study was to determine whether recurrent Dupuytren’s disease after collagenase Clostridium histolyticum treatment differs histologically from recurrence in those treated with fasciectomy. We carried out a prospective cohort study of patients with Dupuytren’s disease who underwent fasciectomy to treat disease recurrence after previous treatment with collagenase Clostridium histolyticum or fasciectomy. The pathologists and statistician were blinded to the previous treatment. Longitudinal biopsy sections were stained with haematoxylin-eosin and the nodular zones were examined. Fifteen patients were studied: nine previously treated with collagenase Clostridium histolyticum and six previously treated with fasciectomy. There were no histological differences between the samples from the two groups of patients. Dupuytren’s disease recurrences after fasciectomy and collagenase Clostridium histolyticum are histologically indistinguishable.

Treatment of Dupuytren's disease using collagenase from Clostridium histolyticum

2013 ◽  
Vol 57 (6) ◽  
pp. 398-402
Author(s):  
M.Á. Martín-Ferrero ◽  
C. Simón-Pérez ◽  
J.I. Rodríguez-Mateos ◽  
B. García-Medrano ◽  
R. Hernández-Ramajo ◽  
...  
Keyword(s):  
Dupuytren’S Disease ◽  
Dupuytren's Disease ◽  
Clostridium Histolyticum

Injectable Collagenase Clostridium Histolyticum: A New Nonsurgical Treatment for Dupuytren's Disease

2010 ◽  
Vol 35 (12) ◽  
pp. 2027-2038.e1 ◽  
Author(s):  
David Gilpin ◽  
Stephen Coleman ◽  
Stephen Hall ◽  
Anthony Houston ◽  
Jeff Karrasch ◽  
...  
Keyword(s):  
Nonsurgical Treatment ◽  
Dupuytren’S Disease ◽  
Collagenase Clostridium Histolyticum ◽  
Dupuytren's Disease ◽  
Clostridium Histolyticum

scholarly journals Examining the Efficacy and Maintenance of Contracture Correction after Collagenase Clostridium Histolyticum Treatment for Dupuytren's Disease

Hand ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. 261-266 ◽  
Author(s):  
Heather A. McMahon ◽  
Abdo Bachoura ◽  
Sidney M. Jacoby ◽  
David S. Zelouf ◽  
Randall W. Culp ◽  
...  
Keyword(s):  
Dupuytren’S Disease ◽  
Collagenase Clostridium Histolyticum ◽  
Dupuytren's Disease ◽  
Clostridium Histolyticum

scholarly journals Hand function 5 years after treatment with collagenase Clostridium histolyticum injection for Dupuytren’s disease

2021 ◽  
pp. 175319342110023
Author(s):  
Ingrid Göransson ◽  
Lars Brudin ◽  
Andra Irbe ◽  
Christina Turesson
Keyword(s):  
Range Of Motion ◽  
Hand Function ◽  
Treatment Method ◽  
Dupuytren’S Disease ◽  
Collagenase Clostridium Histolyticum ◽  
Extension Deficit ◽  
Level Of Evidence ◽  
Dupuytren's Disease ◽  
Clostridium Histolyticum ◽  
New Treatment

The aim of this study was to report hand function, disability and satisfaction and patients’ perception of functionally troublesome contractures 5 years after injection with collagenase Clostridium histolyticum and hand therapy for Dupuytren's disease. Data from 79 patients were collected before and at 3, 12 and 60 months after treatment. Hand function was significantly improved, and 70% achieved a functional range of motion in the treated hand. QuickDASH scores and range of motion were best at 3 months follow-up. At 60 months, mean total extension deficit was 48°, which was 57% of the deficit before treatment. Thirty-seven patients (47%) had developed recurrent contractures in treated finger(s) meeting the criteria for new treatment. The threshold for functionally troublesome contractures was found to be 30°–60° in the finger joints. Treatment was experienced as painful, but few hand function problems occurred. Most patients would choose this treatment method again. Level of evidence: IV

Sign in / Sign up

Export Citation Format

Share Document